us to evaluate the magnitude of in vitro uricolytic activity of Rasburicase, and we undertook two experiments. We retrieved a sample from day 8 of admission [pre-Rasburicase plasma uric acid concentration, 1.59 mmol/L (270 mg/L)] and another from day 14 of admission [post-Rasburicase plasma uric acid concentration, Ͻ0.05 mmol/L (Ͻ8 mg/L)]. These two samples had been stored at 4°C. In the first experiment, we mixed the day 8 and day 14 samples in equal proportions (0.5 mL:0.5 mL). This sample was kept at room temperature (ϳ25°C), and uric acid analysis was performed at 30-min intervals for 3 h. As seen in Fig.  1 (RT1), there was a rapid decrease in uric acid concentrations within 3 h, confirming ongoing in vitro enzymatic degradation of uric acid.
In the second experiment, we allowed one aliquot of the mixed sample (as above) to stand at room temperature and kept another at 4°C. This experiment was carried out on day 26, but the two samples were taken on days 8 and 14, respectively. In vitro enzymatic uric acid degradation in the mixed samples continued at room temperature (RT2). The uric acid concentrations remained relatively stable in the sample maintained at 4°C. The change from baseline to 6 h was 0.05 mmol/L (8 mg/L) and was not statistically significant. This finding demonstrates that the in vitro uricolytic activity of Rasburicase is minimized in a sample maintained at 4°C as reported previously (1, 3 ) .
We conclude that, in monitoring uric acid concentrations in patients receiving recombinant uric acid oxidase therapy, blood samples should be kept on ice immediately after collection, during specimen transport, and before analysis. As long as compliance of sample handling is achieved at 4°C, the results of uric acid measurements should be valid. 
Clinical Capillary Zone Electrophoresis of Serum Proteins: Balancing High Sensitivity and High Specificity
To the Editor: Capillary zone electrophoresis (CZE) is documented to have high sensitivity and specificity for the detection of monoclonal (M) proteins. In two large (Ͼ1500 participants) prospective studies in which CZE was compared with "immunofixation/immunoelectrophoresis", the sensitivity of CZE was 95% (1, 2 ) . This is superior to the sensitivity of agarose gel electrophoresis (AGE), which Katzmann et al. (1 ) found to be 91% and Meunier (3 ) found to be 92.2% (evaluation of 2060 sera containing an M-protein). Especially in the ␤-globulin region, CZE with Paragon CZE 2000 (Beckman-Coulter) is superior to AGE for detection of low-concentration M-proteins (IgA and light chains) (3, 4 ) . The specificity of CZE is reported to be high (98.6%) and comparable to that of AGE (1, 5 ) .
In a prospective study (2 ), we described three M-proteins with high pI values that migrated in the slow ␥ region on AGE but were not detected with Paragon. In addition, one highconcentration IgG with a pI Ϸ7 that migrated in the mid-␥ region on AGE was not separated by CZE. The Paragon has recently been upgraded [modified buffer, higher voltage (10.3 kV), more efficient cooling, adapted software (1.6.02)], and according to the manufacturer, this should have improved resolution of certain rarely occurring M-proteins. With the updated system, ␤-lipoprotein and fibrinogen were also resolved, which was not the case under earlier operating conditions.
The aim of the study was twofold: (a) we evaluated whether the upgrade enhanced resolution of previously unresolved M-proteins and in increased overall sensitivity; and (b) we evaluated whether the increased resolution affected specificity. One could hypothesize that because of the higher resolution, clinically unimportant heterogeneity in the ␥-globulin zone will be observed more frequently.
To address the question of whether the upgrade increased resolution of previously unresolved Mproteins, we reanalyzed four sera that we described to contain a Mprotein that could be separated by AGE but not by CZE (2 ). An additional similar sample with a M-protein migrating in the slow ␥ region with AGE but not with CZE was analyzed as well. Of the four post-␥-migrating M-proteins, one M-protein was detected with the new buffer system, one generated an error code, and two were missed. The high-concentration IgG M-protein with a pI Ϸ7 that migrated in the mid-␥ region on AGE (2 ) was not separated by CZE under software version 1.6.02 but gave an error code.
Collectively, the recently introduced new buffer system for CZE with the Paragon CZE system has a slightly increased sensitivity for detecting M-proteins that were previously missed. Some rare M-proteins Clinical Chemistry 49, No. 8, 2003 still remain unrecognized under these new operating conditions.
In the second part, we assessed the sensitivity and specificity in a prospective study. CZE analysis (Paragon CZE 2000, software version 1.602) and immunofixation (Hydrasys; Sebia) were performed on 1106 consecutive samples submitted to our laboratory to screen for the presence of a M-protein or to reevaluate a known M-protein. The results are shown in Table 1 . The sensitivity of CZE for the detection of M-proteins was 95%, which is similar to the previously reported sensitivity of 95% (1, 2 ) . The M-proteins missed were present in low concentrations except for the IgG M-protein. The specificity of CZE 1.6 to detect Mproteins was calculated to be 78%. This is appreciably lower than the specificity of 98.6% published in an earlier report (2 ) . The most frequently observed abnormalities in immunofixation-negative samples are slight changes in the morphology of the anodal part of the ␥-globulin fraction. This might be attributable to complement degradation in aging samples or to fibrinogen in incompletely clotted serum samples.
In conclusion, the adapted system did show somewhat improved resolution of certain (but not all) rarely occurring M-proteins that were missed by CZE operating under previous software versions and buffer conditions. Because the frequency of these rare slow-␥-migrating M-proteins is extremely low, overall sensitivity (95%) was not influenced. There remain uncommon samples in which AGE is able but CZE is unable to separate the M-protein correctly. Efforts to improve the resolution of CZE for certain rarely occurring Mproteins did not produce an overall increased sensitivity for the detection of M-proteins but did decrease the specificity. The decrease in specificity (to 78%) may have consequences, such as increased costs for follow-up immunofixation analyses. It should be mentioned, however, that falsepositive rates should decrease as operators become more familiar with the new pattern of enhanced resolution. 
Godelieve Mariën

Representatives of Beckman Coulter respond:
To the Editor: We wish to address two points relative to the above letter by Mariën et al.:
(a) Mariën et al. state that the recent operating changes incorporated in Version 1.6.02 of Beckman Coulter's Paragon CZE 2000 have adversely affected specificity, and claim that specificity has decreased to 82%.
In fact, CZE Version 1.6.02 offers improved specificity through enhanced resolution of the serum protein pattern. This enhanced resolution often detects minor degradation proteins that formerly were not readily observable. The enhanced operating conditions also produce a faster migrating gamma zone that appears as a taller, narrower band and, in some cases, may appear as a peak to operators trained on previous patterns. As operators become more familiar with the enhanced CZE patterns, their ability to interpret the patterns improve and falsepositive rates decrease.
(b) Mariën et al. note that one of their previous monoclonal samples gave a suppressed result on the CZE, and they considered this to be a false negative.
In fact, this appears to have resulted from the very high protein concentrations in the sample. The "Instructions For Use" state that samples giving a suppressed result flag should be diluted and rerun. Had the sample been diluted and rerun, we believe that an accurate result would have been obtained. Method Evaluation for Total ␤-Human Chorionic Gonadotropin Using Urine and the ADVIA Centaur
Kevin Day
To the Editor:
We recently described the use of a quantitative serum human chorionic gonadotropin (hCG) assay with urine samples (1 ). Quantitative urine hCG assays are important in validations of point-of-care qualitative hCG tests and in cases of suspected falsepositive quantitative serum hCG results because of heterophilic antibodies (2, 3 ) . Here, we report our study of the ADVIA Centaur ® (Bayer Corporation) total-hCG (ThCG) serum assay with urine.
Recovery of hCG (US Pharmacopeia) added to urine was Ͼ100% at all concentrations (Table 1) . At concentrations Յ200 IU/L, recovery was Ͼ130%. Urine hCG measurements Յ200 IU/L were linear but were not parallel to expected amounts. For samples with results Ͻ200 IU/L, the concentration of hCG in the urine was equal to (measured concentration Ϫ 12 IU/L)/1.3.
We added hCG at final concentrations that ranged from 25 to 500 IU/L into four different matrices as follows: 1) urine from premenopausal, nonpregnant females (as above); 2) saline; 3) Bayer ThCG diluent (buffered heat-treated equine serum with EDTA, sodium azide, and preservatives); and 4) pooled serum from male subjects. Recoveries from diluent and serum were within 15% of expected amounts, whereas recoveries from saline were as great as 150%, similar to those seen in urine (Fig. 1 , available as a Data Supplement accompanying the online version of this Letter at http://www.clinchem. org/content/vol49/issue8/). Imprecision (CV) of twice-daily measurements over 10 days was 4.7%, 5.6%, and 3.6% at 38, 143, and 690 IU/L, respectively. This imprecision is similar to that seen with the Abbott AxSYM assay for urine hCG in our laboratory, which has CVs of 9.5%, 4.7%, and 7.6% at 17, 397, and 781 IU/L, respectively. Intraassay imprecision (n ϭ 10) was 1.7%, 3.8%, and 3.9%, respectively, at these concentrations.
The detection limit was evaluated by measuring total ␤-hCG in urine, from 40 premenopausal, nonpregnant females and 10 males, that presumably contained no hCG. The detection limit, calculated as the mean (SD), was 14 (3) IU/L. The detection limit stated by the manufacturer for serum is 10 IU/L.
To estimate the lower limit of the reportable range, we measured total ␤-hCG in duplicate in urine with 2.5-50 IU/L hCG added. Results were linear from 15 to 50 IU/L but deviated from expected amounts at concentrations Ͻ15 IU/L. We evaluated the results by adding hCG to urine from a premenopausal, nonpregnant female at concentrations from 25 to 500 IU/L. Total ␤-hCG was measured in duplicate. The assay was linear to 300 IU/L in urine samples compared with 1000 IU/L in serum.
Urine hCG results should be interpreted with caution because they vary with fluid intake. Serum-hCGpositive individuals may test negative by a urine hCG test because of very dilute urine. This is true for all urine pregnancy tests.
In conclusion, the ADVIA Centaur seems to provide an adequate detection limit for confirming results from point-of-care devices that detect hCG concentrations Ն20 IU/L (4 ). This method could also be useful in cases of persistent low-positive serum hCG that are potentially attributable to heterophilic antibodies. Recovery of hCG added to urine is Ͼ100% at concentrations Ͻ200 IU/L. We recommend that this method, when used for urine hCG testing, be used only as a qualitative assay. 
